Search results for "progress"

showing 10 items of 1620 documents

Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hemat…

2004

BACKGROUND Continuous oral treatment with topotecan may be more effective than the typical 1-day and 5-day treatment schedules. In previous studies of continuous treatment with topotecan, increased intestinal side effects were reported in adult patients; however, the experience in pediatric patients and patients with high-grade glioma is quite limited. METHODS Thirty-two pediatric patients with recurrent high-grade glioma (16 females and 16 males; median age, 9.5 years) were enrolled in the current Phase I/II study. Tumor locations included the cerebral cortex (n = 5), pons (n = 18), and other sites (n = 9). An injectable formulation of topotecan was administered orally, in ice-cold orange …

MaleCancer Researchmedicine.medical_specialtyAdolescentAdministration OralAntineoplastic AgentsGastroenterologyDrug Administration Schedule03 medical and health sciences0302 clinical medicinePharmacokineticsOral administrationInternal medicineGliomaMedicineHumansDosingChild030304 developmental biologyOrange juice0303 health sciencesbusiness.industryBrain NeoplasmsGliomamedicine.disease3. Good healthSurgeryTreatment OutcomeOncology030220 oncology & carcinogenesisChild PreschoolToxicityTopotecanFemalebusinessTopotecanProgressive diseasemedicine.drugCancer
researchProduct

Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival.

2010

Abstract Aims The role of IGF system in the pathogenesis of Ewing’s sarcoma (EWS) is well-documented. However, still little information is available about the value of IGF system components as indicators of prognosis. Understanding the clinical role for IGF system in EWS patients may be important because different subtypes of patients have distinct outcome and may require different treatment protocol. We evaluated the expression of insulin-like growth factor (IGF)-receptor (IGF-IR), insulin receptor (IR), IGF-I and some major intracellular mediators (IRS1, p-ERK) in specimens from EWS patients with primary localised untreated tumours. Patients and methods 290 samples were used for immunohis…

MaleCancer Researchmedicine.medical_specialtyAdolescentmedicine.medical_treatmentEnzyme-Linked Immunosorbent AssaySarcoma EwingPathogenesisInsulin-like growth factorInternal medicinemedicineHumansInsulin-Like Growth Factor IReceptorChildbiologyReverse Transcriptase Polymerase Chain ReactionEwing's sarcomaCancermedicine.diseasePrognosisImmunohistochemistryIRS1Gene Expression Regulation NeoplasticInsulin receptorEndocrinologyTreatment OutcomeOncologybiology.proteinCancer researchDisease ProgressionFemaleSarcomaEuropean journal of cancer (Oxford, England : 1990)
researchProduct

High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma.

2000

BACKGROUND The lungs are a frequent site of metastasis in patients with melanoma, and this may cause respiratory problems in the terminal phase of the illness. Inhalation interleukin (IL)-2 therapy to the lung has been piloted and appears to be well tolerated. METHODS Twenty-seven patients were treated with single agent dacarbazine and concurrent high dose inhalation IL-2 36 million IU per day). The patients previously had progressed on chemotherapy, predominately dacarbazine-based regimens. Patients included those with American Joint Committee on Cancer Stage IV melanoma, predominately those with lung metastases, but patients with extrapulmonary metastases also were allowed on the study. R…

MaleCancer Researchmedicine.medical_specialtyLung NeoplasmsDacarbazinemedicine.medical_treatmentAntineoplastic AgentsGastroenterologyMetastasisInternal medicineCause of DeathAdministration InhalationAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAntineoplastic Agents AlkylatingMelanomaChemotherapyInhalationbusiness.industryMelanomaRespiratory diseaseRemission InductionCancerReproducibility of ResultsConfounding Factors Epidemiologicmedicine.diseaseRecombinant ProteinsSurgeryDacarbazineTreatment OutcomeOncologyConcomitantDisease ProgressionInterleukin-2FemaleSafetybusinessmedicine.drugFollow-Up StudiesCancer
researchProduct

Rapid progression from oral leukoplakia to carcinoma in an immunosuppressed liver transplant recipient

2002

Immunosuppression used to avoid graft rejection in solid organ transplantation recipients leads to a variety of side-effects, and an increased rate of infections and de novo malignancies. Oral conditions usually associated with immunosuppressive drugs include fungal and viral infection, and lip lesions, but intra-oral carcinoma has not been reported as having a high incidence. This report deals with a male liver transplant recipient receiving FK506 (5 mg/day) and prednisone (20 mg/day) who was diagnosed with a homogeneous leukoplakia on the floor of the mouth 4 months after transplantation, and 4 months later with a squamous cell carcinoma growth at the site of this lesion. The rapid transf…

MaleCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentGastroenterologyTacrolimusLesionPrednisoneInternal medicinemedicineCarcinomaHumansRisk factorLeukoplakiaImmunosuppression Therapybusiness.industryCancerImmunosuppressionMiddle Agedmedicine.diseaseLiver TransplantationTransplantationstomatognathic diseasesOncologyCarcinoma Squamous CellDisease ProgressionPrednisoneMouth NeoplasmsLeukoplakia OralOral Surgerymedicine.symptombusinessImmunosuppressive Agentsmedicine.drugOral Oncology
researchProduct

Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.

2015

Purpose Recent literature reports a potential association between high vitamin D and improved lymphoma prognosis. We evaluated the impact of pretreatment vitamin D on follicular lymphoma (FL) outcome. Patients and Methods SWOG participants were previously untreated patients with FL enrolled onto SWOG clinical trials (S9800, S9911, or S0016) involving CHOP chemotherapy plus an anti-CD20 antibody (rituximab or iodine-131 tositumomab) between 1998 and 2008. Participants included in our second independent cohort were also previously untreated patients with FL enrolled onto the Lymphoma Study Association (LYSA) PRIMA trial of rituximab plus chemotherapy (randomly assigned to rituximab maintenanc…

MaleCancer Researchmedicine.medical_specialtyTime FactorsFollicular lymphomaKaplan-Meier EstimateCHOPGastroenterologyTositumomabDisease-Free SurvivalRisk FactorsTandem Mass SpectrometryInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineVitamin D and neurologyHumansProspective StudiesVitamin DProspective cohort studyCyclophosphamideLymphoma FollicularProportional Hazards Modelsbusiness.industryHazard ratioAntibodies MonoclonalORIGINAL REPORTSMiddle Agedmedicine.diseaseVitamin D DeficiencySurgeryTreatment OutcomeOncologyDoxorubicinVincristineCohortDisease ProgressionPrednisoneRituximabFemalebusinessRituximabBiomarkersmedicine.drugChromatography LiquidJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Postponed Is Not Canceled: Role of Craniospinal Radiation Therapy in the Management of Recurrent Infant Medulloblastoma—An Experience From the HIT-RE…

2013

Purpose To evaluate the efficacy of craniospinal irradiation (CSI) in the management of recurrent infant medulloblastoma after surgery and chemotherapy alone. Methods and Materials Seventeen pediatric medulloblastoma patients registered in the HIT-REZ 1997 and 2005 studies underwent CSI as salvage treatment at first recurrence. All patients had achieved complete remission after first-line treatment consisting of surgery and chemotherapy. Eleven patients showed metastatic disease at relapse. Five patients underwent surgery prior to radiation therapy, which resulted in complete resection in 1 case. In 1 patient, complete resection of the residual tumor was performed after CSI. Eleven patients…

MaleCancer Researchmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMedizinDisease-Free SurvivalCraniospinal IrradiationCohort Studies03 medical and health sciences0302 clinical medicineRecurrencemedicineHumansRadiology Nuclear Medicine and imagingNeoplasm MetastasisChildNeoplasm StagingProportional Hazards ModelsSalvage TherapyMedulloblastomaChemotherapyUnivariate analysisRadiationBrain Neoplasmsbusiness.industryProportional hazards modelInfantRadiotherapy Dosagemedicine.disease3. Good healthSurgeryRadiation therapyTreatment OutcomeOncologyChild Preschool030220 oncology & carcinogenesisMultivariate AnalysisFemaleCranial IrradiationNeoplasm Recurrence LocalbusinessCraniospinal030217 neurology & neurosurgeryProgressive diseaseFollow-Up StudiesMedulloblastomaInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-…

2004

Abstract Based on the results of combined data from three North American Phase II studies, a randomised Phase II study in the same patient population was performed, using combination chemotherapy with estramustine phosphate (EMP) and vinblastine (VBL) in hormone refractory prostate cancer patients. In all, 92 patients were randomised into a Phase II study of oral EMP (10 mg kg day continuously) or oral EMP in combination with intravenous VBL (4 mg m(2) week for 6 weeks, followed by 2 weeks rest). The end points were toxicity and PSA response in both groups, with the option to continue the trial as a Phase III study with time to progression and survival as end points, if sufficient responses…

MaleCancer Researchmedicine.medical_specialtyUrologyAdministration OralPhases of clinical researchVinblastineMetastasisClinicalProstate cancerAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions IntravenousSurvival analysishormone-escaped prostate cancerEMP/VBL vs EMPbusiness.industryProstatic NeoplasmsCombination chemotherapyProstate-Specific Antigenmedicine.diseaseSurvival AnalysisPhase IISurgeryVinblastineProstate-specific antigenOncologyDrug Resistance NeoplasmDisease ProgressionEstramustineEstramustinebusinessmedicine.drug
researchProduct

Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer.

2014

ABSTRACT:  Aims: To assess the utility of dynamic contrast-enhanced MRI parameters in the demonstration of early antiangiogenic effects and as prognostic biomarkers in second-line treatment of advanced-stage non-small-cell lung cancer with vatalanib. Patients & methods: The transfer constant (Ktrans) and the initial area under the contrast concentration–time curve at 60 s (AUC60) were assessed in 46 patients. Changes were compared with response evaluation from computed tomography imaging and Response Evaluation Criteria In Solid Tumors guidelines. Results: Statistically significant mean reductions in Ktrans (38.4%; p < 0.0001) and AUC60 (24.9%; p < 0.0001) were found at day 2. Af…

MaleCancer Researchmedicine.medical_specialtyVatalanibDrug-Related Side Effects and Adverse ReactionsPyridinesMedizinContrast MediaAngiogenesis InhibitorsStable DiseaseText miningCarcinoma Non-Small-Cell LungmedicineHumansIn patientLung cancerAgedNeoplasm StagingClinical Trials as Topicbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance ImagingRadiographyOncologyResponse Evaluation Criteria in Solid TumorsDynamic contrast-enhanced MRIDrug EvaluationPhthalazinesFemaleRadiologyNuclear medicinebusinessProgressive diseaseBiomarkersFuture oncology (London, England)
researchProduct

Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression.

2006

Chronic inflammation increases the risk of cancer and many cancers, including prostate cancer, arise at sites of chronic inflammation. Inducible nitric oxide synthase (iNOS) is an enzyme dominantly expressed during inflammatory reactions. Although synthesis of high amounts of nitric oxide (NO) by iNOS has been demonstrated in pathophysiological processes, such as acute or chronic inflammation, autoimmune diseases or tumorigenesis, the role of iNOS activity in most of these diseases is poorly understood. Analysing prostate cancer biopsies by immunohistochemistry we found iNOS protein expression in tumor cells strongly paralleled by nitrotyrosine suggesting that iNOS is fully active. In vitro…

MaleCancer Researchmedicine.medical_specialtymedicine.drug_classNitric Oxide Synthase Type IIBiologymedicine.disease_causeNitric OxideProstate cancerProstateInternal medicineCell Line TumorGeneticsmedicineAndrogen Receptor AntagonistsHumansAndrogen Receptor AntagonistsMolecular BiologyReverse Transcriptase Polymerase Chain ReactionCancerProstatic NeoplasmsAndrogenmedicine.diseaseImmunohistochemistryAndrogen receptormedicine.anatomical_structureEndocrinologyTumor progressionReceptors AndrogenDisease ProgressionCarcinogenesisOncogene
researchProduct

Growth Arrest Specific 1 (Gas1) Gene Overexpression in Liver Reduces the In Vivo Progression of Murine Hepatocellular Carcinoma and Partially Restore…

2015

The prognosis of hepatocellular carcinoma patients is usually poor, the size of tumors being a limiting factor for surgical treatments. Present results suggest that the overexpression of Gas1 (growth arrest specific 1) gene reduces the size, proliferating activity and malignancy of liver tumors. Mice developing diethylnitrosamine-induced hepatocellular carcinoma were subjected to hydrodynamic gene delivery to overexpress Gas1 in liver. This treatment significantly (p < 0.05) reduced the number of large tumors, while the difference in the total number of lesions was not significant. Moreover, the number of carcinoma foci in the liver and the number of lung metastases were reduced. These resu…

MaleCarcinoma Hepatocellularlcsh:MedicineCell Cycle ProteinsGene deliveryBiologyGPI-Linked ProteinsReal-Time Polymerase Chain ReactionTransfectionMiceCell Line TumorGene expressionCarcinomamedicineAnimalslcsh:ScienceLungCell ProliferationRegulation of gene expressionMultidisciplinaryMicroarray analysis techniquesLiver Neoplasmslcsh:RCell cyclemedicine.diseaseMolecular biologyHedgehog signaling pathwayGene Expression Regulation NeoplasticLiverHepatocellular carcinomaDisease ProgressionHydrodynamicslcsh:QResearch ArticlePLoS ONE
researchProduct